Moderna plans to file for EUA of COVID-19 shot for very young kids by April end

Last week, Pfizer and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages five to 11 years

Moderna plans to submit an application to the US health regulator for Emergency Use Authorisation (EUA) of its COVID-19 vaccine among kids between the ages of six months to five years by end of the month, a company spokesperson said recently.

The Omicron variant was predominant during Moderna’s paediatric trial, and the drugmaker said two doses were around 38 per cent effective in preventing infections in two-to-five-year-olds and 44 per cent effective for children aged six months to under two years.

Last week, Pfizer and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages five to 11 years.

Earlier this year, the US Food and Drug Administration (FDA) authorised a third dose of the Pfizer/BioNTech vaccine for children aged 12 to 15 years and those aged five through 11 who are immunocompromised.

Edits by EP News Bureau

Covid 19 vaccineCOVID vaccine for kidsModerna
Comments (1)
Add Comment